APA (7th ed.) Citation

F, A., M, P., T, B., G, B., G, B., A, B., . . . A, V. (2023). Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies. Frontiers in oncology, 13, 1212752. https://doi.org/10.3389/fonc.2023.1212752

Chicago Style (17th ed.) Citation

F, Angotzi, et al. "Tixagevimab/Cilgavimab as Pre-exposure Prophylaxis Against SARS-CoV-2 in Patients with Hematological Malignancies." Frontiers in Oncology 13 (2023): 1212752. https://doi.org/10.3389/fonc.2023.1212752.

MLA (9th ed.) Citation

F, Angotzi, et al. "Tixagevimab/Cilgavimab as Pre-exposure Prophylaxis Against SARS-CoV-2 in Patients with Hematological Malignancies." Frontiers in Oncology, vol. 13, 2023, p. 1212752, https://doi.org/10.3389/fonc.2023.1212752.